Clene Inc Ordinary Shares CLNN 深 沪
等待开盘 08-06 09:30:00 美东时间
3.69
-0.050
-1.34%
华盛通- 最 高3.785
- 今 开3.73
- 成交量 3.83万股
- 最 低 3.62
- 昨 收 3.74
- 总市值 3314.62万
- 52周最高 6.90
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 2.2801
- 委 比 86.57%
- 总股本 898.27万
- 历史最高 356.40
- 量 比 0.30
- 振 幅 4.41%
- 历史最低 2.2801
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clene to Present at the Canaccord 45th Annual Growth Conference
Clene Inc. announced that its management will present at the Canaccord 45th Annual Growth Conference on August 12, 2025, at 3:30pm ET in Boston. The presentation will cover Clene’s late clinical-stage biopharmaceutical developments, particularly CNM-Au8® for neurodegenerative diseases like ALS and MS. A webcast is available on Clene’s website, and 1x1 investor meetings can be arranged through Canaccord representatives.
08-05 12:30
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DIH Holding US (NASDAQ:DHAI) shares rose 35.1% to $0.34 during Friday'...
07-19 05:06
Clene Files Prospectus for Additional Share Offering
Clene ( ($CLNN) ) has shared an announcement. On April 28, 2025, Clene Inc. ent...
07-04 04:59
进步派的建制时刻：奥克兰市长选举背后的美国民主党路线之争
在以往，一座中型城市的市长选举很少能引起本地之外的广泛关注。然而，2025年4月举行的加州奥克兰市长选举却成了例外——不仅吸引了全国政治观察者的目光，还占据了...
07-02 13:58
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
07-01 01:06
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Clene, Inc. announced regulatory updates following a Type C meeting with the FDA, including supportive feedback on its proposed statistical analysis plan (SAP) for neurofilament light (NfL) biomarker analysis in its NIH-sponsored Expanded Access Program (EAP) for ALS. The NfL analyses are expected to be conducted early in the 4th quarter of 2025. The company also confirmed two additional FDA meetings in the 3rd quarter of 2025 to discuss ALS surv...
06-30 12:00
卖家穿海受邀出席世界跨境电商发展大会，分享AI赋能选品的创新实践
转自：蚌埠新闻网 2025年6月17日，“2025世界跨境电商发展大会”在廊坊临空国际会展中心召开。卖家穿海受邀出席本次大会，创始人Jason在跨境电商AI应用...
06-20 10:53
